Suppr超能文献

具有 P2' 谷氨酸的简单拟二肽:基质金属蛋白酶和其他金属蛋白酶的新型抑制剂家族。

Simple pseudo-dipeptides with a P2' glutamate: a novel inhibitor family of matrix metalloproteases and other metzincins.

机构信息

CEA (Commissariat à l'Energie Atomique), iBiTec-S, Service d'Ingénierie Moléculaire de Protéines (SIMOPRO), CE Saclay, 91191 Gif/Yvette, Cedex, France.

出版信息

J Biol Chem. 2012 Aug 3;287(32):26647-56. doi: 10.1074/jbc.M112.380782. Epub 2012 Jun 11.

Abstract

A series of pseudo-peptides with general formula X-l-Glu-NH(2) (with X corresponding to an acyl moiety with a long aryl-alkyl side chain) have been synthesized, evaluated as inhibitors of matrix metalloproteases (MMPs), and found to display remarkable nanomolar affinity. The loss in potency associated with a substitution of the P(2)' l-glutamate by a l-glutamine corroborates the importance of a carboxylate at this position. The binding mode of some of these inhibitors was characterized in solution and by x-ray crystallography in complex with various MMPs. The x-ray crystal structures reveal an unusual binding mode with the glutamate side chain chelating the active site zinc ion. Competition experiments between these inhibitors and acetohydroxamic acid, a small zinc-binding molecule, are in accord with the crystallographic results. One of these pseudo-dipeptides displays potency and selectivity toward MMP-12 similar to the best MMP-12 inhibitors reported to date. This novel family of pseudo peptides opens new opportunities to develop potent and selective inhibitors for several metzincins.

摘要

已合成了一系列通式为 X-l-Glu-NH(2) 的拟肽(其中 X 对应于具有长芳基-烷基侧链的酰基部分),并将其评估为基质金属蛋白酶(MMPs)的抑制剂,发现它们具有显著的纳摩尔亲和力。用 l-谷氨酰胺替代 P(2)'l-谷氨酸所导致的效力损失证实了该位置羧酸酯的重要性。这些抑制剂中的一些在溶液中和与各种 MMP 形成复合物的 X 射线晶体结构中进行了特征描述。X 射线晶体结构揭示了一种不寻常的结合模式,谷氨酸侧链螯合活性部位锌离子。这些抑制剂与乙二醛肟酸(一种小分子锌结合分子)之间的竞争实验与晶体学结果一致。这些拟二肽之一对 MMP-12 的效力和选择性与迄今为止报道的最佳 MMP-12 抑制剂相似。这种新型拟肽家族为开发几种金属蛋白酶的有效且选择性抑制剂提供了新的机会。

相似文献

1
Simple pseudo-dipeptides with a P2' glutamate: a novel inhibitor family of matrix metalloproteases and other metzincins.
J Biol Chem. 2012 Aug 3;287(32):26647-56. doi: 10.1074/jbc.M112.380782. Epub 2012 Jun 11.
3
Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
J Med Chem. 1997 Mar 14;40(6):1026-40. doi: 10.1021/jm960465t.
6
9
Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation.
J Biol Chem. 2010 Nov 12;285(46):35900-9. doi: 10.1074/jbc.M110.139634. Epub 2010 Sep 3.

引用本文的文献

1
Interactions of substrates and phosphinyl containing inhibitors with bacterial and human zinc proteases.
PLoS One. 2025 Aug 1;20(8):e0329362. doi: 10.1371/journal.pone.0329362. eCollection 2025.
3
Phosphinic Peptides as Tool Compounds for the Study of Pharmacologically Relevant Zn-Metalloproteases.
ACS Pharmacol Transl Sci. 2022 Nov 28;5(12):1228-1253. doi: 10.1021/acsptsci.2c00183. eCollection 2022 Dec 9.
5
Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening.
Molecules. 2021 Jul 28;26(15):4553. doi: 10.3390/molecules26154553.
7
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.
J Cell Biochem. 2017 Nov;118(11):3531-3548. doi: 10.1002/jcb.26185. Epub 2017 Jul 17.
9
Synthesis and in Vitro and in Vivo Evaluation of MMP-12 Selective Optical Probes.
Bioconjug Chem. 2016 Oct 19;27(10):2407-2417. doi: 10.1021/acs.bioconjchem.6b00377. Epub 2016 Sep 14.
10
Regulation and involvement of matrix metalloproteinases in vascular diseases.
Front Biosci (Landmark Ed). 2016 Jan 1;21(1):89-118. doi: 10.2741/4378.

本文引用的文献

2
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.
Bioorg Med Chem Lett. 2012 Jan 1;22(1):271-7. doi: 10.1016/j.bmcl.2011.11.034. Epub 2011 Nov 16.
3
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
Bioorg Med Chem Lett. 2011 Dec 1;21(23):7180-4. doi: 10.1016/j.bmcl.2011.09.077. Epub 2011 Sep 22.
4
Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis.
Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2464-72. doi: 10.1161/ATVBAHA.111.231563.
5
Matrix metalloproteinases as drug targets in ischemia/reperfusion injury.
Drug Discov Today. 2011 Sep;16(17-18):762-78. doi: 10.1016/j.drudis.2011.06.009. Epub 2011 Jul 2.
6
Selective non zinc binding inhibitors of MMP13.
Bioorg Med Chem Lett. 2011 Jul 15;21(14):4215-9. doi: 10.1016/j.bmcl.2011.05.075. Epub 2011 May 27.
7
A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice.
Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):528-35. doi: 10.1161/ATVBAHA.110.219147. Epub 2011 Jan 6.
8
Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation.
J Biol Chem. 2010 Nov 12;285(46):35900-9. doi: 10.1074/jbc.M110.139634. Epub 2010 Sep 3.
9
Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity.
Biochimie. 2010 Nov;92(11):1501-8. doi: 10.1016/j.biochi.2010.07.017. Epub 2010 Aug 7.
10
SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability.
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5039-43. doi: 10.1016/j.bmcl.2010.07.036. Epub 2010 Jul 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验